SL VAXIGEN INC has a total of 14 patent applications. It decreased the IP activity by 66.0%. Its first patent ever was published in 2016. It filed its patents most often in Republic of Korea, Taiwan and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, biotechnology and environmental technology are ZHEJIANG REACHALL PHARMACEUTICAL CO LTD, CYTLIMIC INC and ZHUHAI ESSEX BIO PHARMACEUTICAL CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 3 | |
#2 | Taiwan | 3 | |
#3 | WIPO (World Intellectual Property Organization) | 3 | |
#4 | China | 2 | |
#5 | EPO (European Patent Office) | 1 | |
#6 | Hong Kong | 1 | |
#7 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Microorganisms | |
#5 | Peptides |
# | Name | Total Patents |
---|---|---|
#1 | Seo Yong Bok | 8 |
#2 | Sim Sang Hee | 6 |
#3 | Seo Yong-Bok | 6 |
#4 | Choi Youngwoo | 4 |
#5 | Shin Ju-A | 3 |
#6 | Sim Sang-Hee | 3 |
#7 | Shin Ju A | 2 |
#8 | Jin Hyun Tak | 2 |
#9 | Choi Young-Woo | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019151760A1 | Novel multivalent hpv vaccine composition | |
WO2019151759A1 | Novel vaccine immunoadjuvant | |
KR20180035092A | A DNA vaccine for preventing and treating HSV-2 infection |